
This study was performed to evaluate the outcome after zzso zzso zzso of significant bleeding in incurable cancer zzso 

Patients treated by zzso zzso between November 2006 and February 2010 were zzso zzso zzso was assessed according to the World Health Organization zzso scale zzso zzso zzso zzso zzso zzso significant zzso zzso requiring zzso zzso associated with zzso The primary zzso was bleeding at the end of zzso Key secondary zzso included overall survival zzso and acute zzso The bleeding score before and after zzso were compared using the zzso signed rank zzso Time to event zzso were estimated using the Kaplan zzso zzso 

zzso 62 patients were analyzed including 1 patient whose benign cause of bleeding was zzso zzso Median age was 66 zzso zzso zzso Before zzso bleeding was graded as 2 and 3 in 24 zzso and 38 zzso patients, zzso A median dose of 20 zzso zzso zzso of zzso zzso was applied to the bleeding zzso At the end of zzso there was a statistically significant difference in bleeding zzso it was graded as 0 ( zzso 1 ( zzso 2 ( zzso 3 ( zzso and 4 zzso With a median follow-up of zzso zzso zzso months, the zzso zzso rate was zzso Forty patients died zzso 5 due to zzso No grade 3 or above acute toxicity was zzso 

zzso zzso seems to be a safe and effective treatment for clinically and statistically significantly reducing bleeding in incurable cancer zzso 

